ONC – BeOne Medicines Ltd ADR
BeOne Medicines Ltd.ONC
$424.00Name : BeOne Medicines Ltd.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $48,431,857,664.00
EPSttm : 7.92
BeOne Medicines Ltd.
$424.00
1.60%$6.67
ONC — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
1.71
Margin Of Safety %
-15
Put/Call OI Ratio
0.8
EPS Next Q Diff
-1.57
EPS Last/This Y
-0.42
EPS This/Next Y
2.8
Price
424.39
Target Price
462.15
Analyst Recom
1.27
Performance Q
18.09
Upside
-34.9%
Beta
0.62
Ticker: ONC
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | ONC | 350.44 | 0.63 | 0.18 | 1536 |
| 2026-10-13 | ONC | 349.25 | 0.63 | 0.40 | 1556 |
| 2026-10-14 | ONC | 351.57 | 0.62 | 0.25 | 1560 |
| 2026-10-15 | ONC | 374.3 | 0.62 | 0.03 | 1543 |
| 2026-10-16 | ONC | 369.31 | 0.67 | 0.69 | 1476 |
| 2026-10-19 | ONC | 370.36 | 0.74 | 0.36 | 1333 |
| 2026-10-20 | ONC | 384.79 | 0.74 | 0.95 | 1354 |
| 2026-10-21 | ONC | 386.37 | 0.75 | 0.62 | 1410 |
| 2026-10-22 | ONC | 382.59 | 0.75 | 0.06 | 1448 |
| 2026-10-23 | ONC | 377.95 | 0.58 | 0.63 | 1725 |
| 2026-10-26 | ONC | 371.05 | 0.58 | 0.50 | 1746 |
| 2026-10-27 | ONC | 367.05 | 0.59 | 2.73 | 1747 |
| 2026-10-28 | ONC | 373.5 | 0.60 | 0.88 | 1764 |
| 2026-10-29 | ONC | 371.57 | 0.63 | 0.00 | 2059 |
| 2026-10-30 | ONC | 370.29 | 0.63 | 0.00 | 2061 |
| 2026-11-02 | ONC | 361.04 | 0.63 | 8.00 | 2064 |
| 2026-11-03 | ONC | 354.89 | 0.63 | 0.08 | 2066 |
| 2026-11-04 | ONC | 378.19 | 0.63 | 1.98 | 2079 |
| 2026-11-05 | ONC | 387.53 | 0.97 | 0.07 | 3245 |
| 2026-11-06 | ONC | 407.17 | 0.79 | 0.80 | 3633 |
| 2026-11-09 | ONC | 417.6 | 0.80 | 1.02 | 3695 |
| 2026-11-10 | ONC | 424.19 | 0.80 | 0.52 | 3759 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | ONC | 350.40 | 72.3 | 521.9 | 7.62 |
| 2026-10-13 | ONC | 350.86 | 72.3 | 508.3 | 7.64 |
| 2026-10-14 | ONC | 351.45 | 72.3 | 497.7 | 7.64 |
| 2026-10-15 | ONC | 375.01 | 72.3 | 603.4 | 7.64 |
| 2026-10-16 | ONC | 368.56 | 72.3 | 565.0 | 7.64 |
| 2026-10-19 | ONC | 370.04 | 72.3 | 503.2 | 7.64 |
| 2026-10-20 | ONC | 370.04 | 72.3 | 503.2 | 7.64 |
| 2026-10-21 | ONC | 384.79 | 72.3 | 565.9 | 7.64 |
| 2026-10-22 | ONC | 382.27 | 72.3 | 503.4 | 7.64 |
| 2026-10-23 | ONC | 377.94 | 72.3 | 502.6 | 7.64 |
| 2026-10-26 | ONC | 369.77 | 72.7 | 465.9 | 7.64 |
| 2026-10-27 | ONC | 366.47 | 72.7 | 482.2 | 7.64 |
| 2026-10-28 | ONC | 373.91 | 72.7 | 513.7 | 7.64 |
| 2026-10-29 | ONC | 370.54 | 72.7 | 537.4 | 7.64 |
| 2026-10-30 | ONC | 369.53 | 72.7 | 519.2 | 7.64 |
| 2026-11-02 | ONC | 362.39 | 72.7 | 496.3 | 7.64 |
| 2026-11-03 | ONC | 355.00 | 72.7 | 464.3 | 7.64 |
| 2026-11-04 | ONC | 377.88 | 72.7 | 647.6 | 7.64 |
| 2026-11-05 | ONC | 388.51 | 72.7 | 533.8 | 7.64 |
| 2026-11-06 | ONC | 407.61 | 72.7 | 401.9 | 7.64 |
| 2026-11-09 | ONC | 418.03 | 164.0 | 215.7 | 7.64 |
| 2026-11-10 | ONC | 424.39 | 311.1 | 212.4 | 7.64 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | ONC | -64.87 | 1.94 | 1.86 |
| 2026-10-13 | ONC | -64.87 | 1.94 | 1.86 |
| 2026-10-14 | ONC | -64.87 | 1.94 | 1.86 |
| 2026-10-15 | ONC | -64.87 | 1.94 | 1.86 |
| 2026-10-16 | ONC | -65.55 | 1.94 | 1.86 |
| 2026-10-19 | ONC | -65.55 | 1.94 | 1.86 |
| 2026-10-20 | ONC | -65.55 | 1.94 | 1.86 |
| 2026-10-21 | ONC | -65.55 | 1.94 | 1.86 |
| 2026-10-22 | ONC | -65.55 | 1.94 | 1.86 |
| 2026-10-23 | ONC | -65.55 | 1.94 | 1.86 |
| 2026-10-26 | ONC | -65.55 | 1.86 | 1.86 |
| 2026-10-27 | ONC | -65.55 | 1.86 | 1.73 |
| 2026-10-28 | ONC | -65.55 | 1.86 | 1.73 |
| 2026-10-29 | ONC | -65.55 | 1.86 | 1.73 |
| 2026-10-30 | ONC | -66.21 | 1.86 | 1.73 |
| 2026-11-02 | ONC | -66.21 | 2.00 | 1.73 |
| 2026-11-03 | ONC | -66.21 | 2.00 | 1.73 |
| 2026-11-05 | ONC | -66.21 | 2.00 | 1.73 |
| 2026-11-06 | ONC | -66.21 | 2.00 | 1.73 |
| 2026-11-09 | ONC | -66.21 | 1.37 | 0 |
| 2026-11-10 | ONC | -66.01 | 1.37 | 1.71 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
3.64
Avg. EPS Est. Current Quarter
1.53
Avg. EPS Est. Next Quarter
2.07
Insider Transactions
-66.01
Institutional Transactions
1.37
Beta
0.62
Average Sales Estimate Current Quarter
1863
Average Sales Estimate Next Quarter
1783
Fair Value
359.72
Quality Score
96
Growth Score
81
Sentiment Score
100
Actual DrawDown %
-1
Max Drawdown 5-Year %
-68.9
Target Price
462.15
P/E
53.76
Forward P/E
39.77
PEG
0.54
P/S
6.74
P/B
8.31
P/Free Cash Flow
30.72
EPS
7.89
Average EPS Est. Cur. Y
7.64
EPS Next Y. (Est.)
10.45
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
13.86
Relative Volume
1.44
Return on Equity vs Sector %
-10.6
Return on Equity vs Industry %
9.1
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
212.4
◆
ONC
Healthcare
$424.00
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
72.8
Range 1M
99.2%
Sup Dist
3%
Momentum Growth
Ride accelerating trends
WATCH
EPS Yr
229.5%
EPS NY
23%
52W%
99.6%
Long-Term Value
Quality companies, undervalued
WATCH
🔴 SELL
-9.6% upside
Upside
-9.6%
Quality
96
MoS
-15%
ONC — P/E HistoricalBiotechnology
BeOne Medicines Ltd.Sector: Healthcare
Industry: Biotechnology
Employees: 12000
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
ONC
Latest News
—
Caricamento notizie per ONC…
stock quote shares ONC – BeOne Medicines Ltd ADR Stock Price stock today
news today ONC – BeOne Medicines Ltd ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch ONC – BeOne Medicines Ltd ADR yahoo finance google finance
stock history ONC – BeOne Medicines Ltd ADR invest stock market
stock prices ONC premarket after hours
ticker ONC fair value insiders trading